scholarly journals Nutritional Support for a Child With Juvenile Myelomonocytic Leukaemia at Various Stages of Antineoplastic Therapy: A Clinical Case

2019 ◽  
Vol 17 (6) ◽  
pp. 490-495
Author(s):  
Mariam S. Shamsutdinova ◽  
Yulia A. Alymova ◽  
Andrey Yu. Vashura
Keyword(s):  
Antineoplastic Therapy ◽  
Nutritional Support ◽  
Clinical Case ◽  
Malignant Disease ◽  
Clinical Situation ◽  
Hematopoietic Stem ◽  
Oncological Diseases ◽  
Excessive Proliferation ◽  
Vigorous Treatment

Background. Juvenile myelomonocytic leukaemia is a malignant disease with clonal impairment of haematopoiesis, characterized by excessive proliferation of monocytic and granulocytic sprout. Currently, the only way to cure it is hematopoietic stem cell transplantation. Vigorous treatment is accompanied by the development of a large number of complications, including nutritional ones. Nutritional support for these patients is fraught with many difficulties due to the treatment characteristics, patient’s condition, and complications of therapy.Description of a Clinical Case. A child diagnosed with juvenile myelomonocytic leukaemia, 1 year and 11 months old, received antineoplastic therapy — chemotherapy and bone marrow transplantation. In the course of treatment and after it, severe complications developed, which required various types of nutritional support, depending on the clinical situation. It is illustrated how important timely nutritional support is and how long and difficult nutritional disorders can proceed in these children even after termination of the main therapy.Conclusion. Preventive nutritional support with infant formulas is advisable for children with oncological diseases prior to treatment even with normal nutritional indicators. With the potential long-term impossibility of adequate alimentation per os, it is advisable to consider the placement of a gastrostomy tube for enteral nutrition since problems with appetite can be very long.

scholarly journals Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping

2021 ◽  
pp. 154-159
Author(s):  
M. O. Mandrina ◽  
V. V. Breder ◽  
M. V. Ivanov ◽  
A. A. Lebedeva ◽  
V. V. Gorbatsevich ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Malignant Disease ◽  
Clinical Situation ◽  
Malignant Neoplasms ◽  
Molecular Testing ◽  
Tumor Treatment ◽  
Individual Approach ◽  
Oncological Diseases ◽  
The Individual

Personalized therapy is starting to play an increasing role in modern approaches to the treatment of oncological diseases. The previously existing uniform standard for each malignant disease is expanded with new options and treatment possibilities, depending on each specific clinical situation. That increases the  effectiveness of  therapy and helps to control the  disease. A  separate niche in the individual approach to anti-tumor treatment is occupied by targeted therapy of malignancies. There are a lot of mutations that can lead to the emergence of malignant neoplasms. So of all that multitude of choices the individual approach to a patient helps to select the mutations that are most likely to be found in a given patient. The research in the area of the c-MET mutation has allowed it to occupy its niche as a therapeutic target. The identification of this mutation is not included in the routine set of analyses performed for a patient with diagnosed lung adenocarcinoma. But expanding the panel of molecular testing would increase the detectability of this mutation and, as a result, improve the quality of treatment for this category of patients. This clinical case describes the experience of treatment of an elderly patient with lung adenocarcinoma, in whose tumor tissue a MET mutation was detected.

Klinische Langzeitergebnisse der perkutanen transluminalen Angioplastie bei Patienten mit peripherer arterieller Verschlusskrankheit

VASA ◽  
2002 ◽  
Vol 31 (1) ◽  
pp. 36-42 ◽  
Author(s):  
. Bucek ◽  
Hudak ◽  
Schnürer ◽  
Ahmadi ◽  
Wolfram ◽  
...  
Keyword(s):  
Success Rate ◽  
Clinical Stage ◽  
Ankle Brachial Index ◽  
Clinical Situation ◽  
Clinical Results ◽  
Transluminal Angioplasty ◽  
Term Outcome ◽  
Long Term Outcome

Background: We investigated the long-term clinical results of percutaneous transluminal angioplasty (PTA) in patients with peripheral arterial occlusive disease (PAOD) and the influence of different parameters on the primary success rate, the rate of complications and the long-term outcome. Patients and methods: We reviewed clinical and hemodynamic follow-up data of 166 consecutive patients treated with PTA in 1987 in our department. Results: PTA improved the clinical situation in 79.4% of patients with iliac lesions and in 88.3% of patients with femoro-popliteal lesions. The clinical stage and ankle brachial index (ABI) post-interventional could be improved significantly (each P < 0,001), the same results were observed at the end of follow-up (each P < 0,001). Major complications occurred in 11 patients (6.6%). The rate of primary clinical long-term success for suprainguinal lesions was 55% and 38% after 5 and 10 years (femoro-popliteal 44% and 33%), respectively, the corresponding data for secondary clinical long-term success were 63% and 56% (60% and 55%). Older age (P = 0,017) and lower ABI pre-interventional (P = 0,019) significantly deteriorated primary clinical long-term success for suprainguinal lesions, while no factor could be identified influencing the outcome of femoro-popliteal lesions significantly. Conclusion: Besides an acceptable success rate with a low rate of severe complications, our results demonstrate favourable long-term clinical results of PTA in patients with PAOD.

Spontaneous Catheter Separation from the Implanted Venous Port and Its Migration to the Venous Heart: Clinical Case

2018 ◽  
Vol 5 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Lyudmila V. Olkhova ◽  
Vladimir E. Popov
Keyword(s):  
Clinical Case ◽  
Care Delivery ◽  
Venous Access ◽  
Cerebellar Hemisphere ◽  
Clinical State ◽  
Venous Port ◽  
Silicone Catheter ◽  
Oncological Diseases ◽  
Left Cerebellar Hemisphere ◽  
Port Systems

Background. Currently, vascular access is one of the most important aspects in specific and accompanying treatment of cancer patients regardless of their age and sex. Partially implanted venous catheters previously described by Hickman were widely applied all over the world. The introduction of completely implanted venous port-systems revolutionized health care delivery and improved the quality of life in patients with oncological diseases. A fully implanted venous port consists of a silicone catheter which distal tip is connected to a port tank implanted subcutaneously. Such a design allows providing safe and multiple adequate vascular accesses regardless of the patient’s clinical state.Case Report. We present a clinical case of a 10-year-old patient diagnosed with medulloblastoma of the cerebellopontine angle and the left cerebellar hemisphere. The case described spontaneous detachment of an implanted venous port catheter and its migration to the venous heart in a patient who underwent chemotherapy by venous access provided through implantation of the venous port.Conclusion. Our clinical case demonstrated a rare and potentially extremely dangerous noninfectious complication associated with the use of venous port-systems. Implanted systems require washing 1–2 times per month with heparinized solutions or solutions containing taurolidine when they are not used. Periodic chest radiographs can reveal integrity alterations of the system. Any implanted system should be removed when it is not used, or it should be monitored on a regular basis.

CLINICAL CASE OF LONG-TERM RESULTS OF KERATO-REFRACTIVE SURGERIES IN A PATIENT WITH A HIGH MYOPIA

2019 ◽  
Vol 21 (4) ◽  
pp. 14-16
Author(s):  
M.A. Frolov ◽  
◽  
P.A. Gonchar ◽  
V.A. Biletskaya ◽  
E.S. Belyaeva ◽  
...  
Keyword(s):  
High Myopia ◽  
Clinical Case ◽  
Long Term Results
Sign in / Sign up

Export Citation Format

Share Document